These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17428176)

  • 1. Superficial bladder cancer: part 2. Management.
    Josephson D; Pasin E; Stein JP
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):567-81. PubMed ID: 17428176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?
    Schmidbauer J; Lindenau G
    Curr Opin Urol; 2008 Sep; 18(5):504-7. PubMed ID: 18670275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of superficial bladder cancer.
    Dalbagni G
    Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer.
    Barocas DA; Clark PE
    Curr Opin Oncol; 2008 May; 20(3):307-14. PubMed ID: 18391631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
    Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
    J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer.
    Clark PE
    Curr Opin Oncol; 2007 May; 19(3):241-7. PubMed ID: 17414643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.
    Brausi M; Witjes JA; Lamm D; Persad R; Palou J; Colombel M; Buckley R; Soloway M; Akaza H; Böhle A
    J Urol; 2011 Dec; 186(6):2158-67. PubMed ID: 22014799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative instillation therapy in superficial bladder cancer: is it effective regarding outcome and costs?
    Engel RP; Witjes JA
    Curr Opin Urol; 2009 Sep; 19(5):511-5. PubMed ID: 19553821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of intravesical therapy for urothelial cancer of the bladder.
    Koya MP; Simon MA; Soloway MS
    J Urol; 2006 Jun; 175(6):2004-10. PubMed ID: 16697786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
    BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.